Toggle light / dark theme

Wave-based analog computing has recently emerged as a promising computing paradigm due to its potential for high computational efficiency and minimal crosstalk. Although low-frequency acoustic analog computing systems exist, their bulky size makes it difficult to integrate them into chips that are compatible with complementary metal-oxide semiconductors (CMOS). This research paper addresses this issue by introducing a compact analog computing system (ACS) that leverages the interactions between ultrasonic waves and metasurfaces to solve ordinary and partial differential equations. The results of our wave propagation simulations, conducted using MATLAB, demonstrate the high accuracy of the ACS in solving such differential equations. Our proposed device has the potential to enhance the prospects of wave-based analog computing systems as the supercomputers of tomorrow.

🔥Post Graduate Program In AI And Machine Learning: https://www.simplilearn.com/pgp-ai-machine-learning-certific…ce=youtube.
🔥AI & Machine Learning Bootcamp(US Only): https://www.simplilearn.com/ai-machine-learning-bootcamp?utm…ce=youtube.

✅Subscribe to our Channel to learn more about the top Technologies: https://bit.ly/2VT4WtH

⏩ Check out More AI Videos By Simplilearn: https://youtube.com/playlist?list=PLEiEAq2VkUULyr_ftxpHB6DumOq1Zz2hq.

#NLPEngineerRoadmapFor2023 #HowToBecomeNLPEngineer #RoadmapForNLPEngineer #NLP #NaturalLanguageProcessing #MachineLearning #ML #ArtificialIntelligence #AI #Simplilearn.

I will try to live as long as possible.


Dr. Ezekiel Emanuel plans to reject life-extending medical care at the age of 75. The reason he does this is quite similar to why the Kaelons commit ritual suicide in Star Trek: The Next Generation. Does this make sense?

In this thought-provoking episode of Lifespan News, host Ryan O’Shea delves deep into the controversial topic of choosing when to die and the ethics surrounding medical interventions to prolong life. Using the lens of a Star Trek: The Next Generation episode and drawing parallels with Dr. Ezekiel Emanuel’s The Atlantic article, “Why I Hope to Die at 75″, Ryan confronts the moral and societal implications of setting an arbitrary age to stop seeking medical treatment. With advancements in rejuvenation biotechnologies, is it reasonable to maintain such views? As we push the boundaries of science and healthcare, when should we draw the line? Join Ryan as he navigates these complex questions, and remember to share your thoughts in the comments below. Don’t forget to subscribe for more!

The FDA on Friday approved Regeneron Pharmaceuticals’ Veopoz (pozelimab-bbfg), the first and only treatment indicated specifically for CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, according to the company.

A fully human monoclonal antibody, Veopoz is approved for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE, an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms.

- CHAPLE—which stands for complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy—is an inherited immune disease that causes the complement system (the part of your immune system that defends the body against injury and foreign invaders like bacteria and viruses) to become overactive.-FDA.


The regulator’s greenlight on Friday for Regeneron Pharmaceuticals’ monoclonal antibody Veopoz (pozelimab-bbfg) makes it the first and only treatment indicated for children and adults with CHAPLE disease.